AVEO Quote, Trading Chart, AVEO Pharmaceuticals Inc.
home / stock / aveo / aveo quote
$8.26 Last:
1.1% Change Percent:
$8.19 Open:
$8.26 Previous Close:
$8.42 High:
$7.85 Low:
313,658 Volume:
02/26/2021 04:55:19 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-26 | 8.19 | 8.26 | 8.42 | 7.85 | 313,658 |
| 2021-02-25 | 8.54 | 8.17 | 8.73 | 8.05 | 316,247 |
| 2021-02-24 | 8.75 | 8.67 | 8.87 | 8.47 | 292,855 |
| 2021-02-23 | 8.49 | 8.65 | 8.8 | 7.81 | 538,353 |
| 2021-02-22 | 8.97 | 8.78 | 9.5 | 8.65 | 581,535 |
| 2021-02-19 | 9.1 | 8.91 | 9.21 | 8.7 | 500,952 |
| 2021-02-18 | 8.98 | 8.75 | 9.13 | 8.27 | 844,673 |
| 2021-02-17 | 8.27 | 8.31 | 8.37 | 8.03 | 223,212 |
| 2021-02-16 | 8.66 | 8.44 | 8.7373 | 8.15 | 295,415 |
| 2021-02-15 | 8.25 | 8.49 | 8.71 | 8.09 | 321,760 |
| 2021-02-12 | 8.25 | 8.49 | 8.71 | 8.09 | 319,997 |
| 2021-02-11 | 9.08 | 8.14 | 9.1 | 8.08 | 652,729 |
| 2021-02-10 | 9.1 | 8.78 | 9.205 | 8.64 | 385,489 |
| 2021-02-09 | 9.52 | 8.93 | 9.6125 | 8.81 | 579,771 |
| 2021-02-08 | 9.2 | 9.56 | 9.7 | 9.0369 | 581,813 |
| 2021-02-05 | 9.11 | 9.115 | 9.2 | 8.58 | 383,963 |
| 2021-02-04 | 8.46 | 8.95 | 9.01 | 8.3828 | 426,309 |
| 2021-02-03 | 8.37 | 8.35 | 8.5681 | 8.23 | 264,763 |
| 2021-02-02 | 8.13 | 8.29 | 8.7 | 8 | 404,314 |
| 2021-02-01 | 7.95 | 7.96 | 8.18 | 7.8201 | 269,646 |
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
-
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time. A live webcast of t...
-
– Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST Quality of Life Measure Shows Significant Improvement for Tivozanib over Sorafenib – AVEO Oncology ...
-
– $20M Tranche Available on Approval of Tivozanib – AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, ...